An Unusual Overdose of Leflunomide in a Patient with Rheumatoid Arthritis

Abstract

Get full access to this article

View all access options for this article.

References

Aventis Pharmaceuticals and FDA updated the prescribing information for Arava (leflunomide), indicated for the treatment of active rheumatoid arthritis. MedWatch Safety Information. www.fda.gov/medwatch/SAFETY/2003/Arava_Pl.pdf (accessed 2003 Nov 29).

Mladenovic

Domljan

Rozman

Jajic

Mihajlovic

Dordevic

Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, Phase II study. Arthritis Rheum 1995;38:1595–603.

Jakez-Ocampo

Richaud-Patin

Simon

Llorente

Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: An open pilot comparative study. Joint Bone Spine 2002;69:307–11.